Artemis Therapeutics, Inc. (ATMS) is a biopharmaceutical company developing novel treatments for serious and life-threatening infections. The company’s lead drug candidate, Artemisone, is a best-in-class artemisinin which has been studied in a phase 2 clinical trial for the treatment of malaria (p. falciparum) and is currently undergoing in vitro evaluation for its activity against human cytomegalovirus (CMV), including transplant CMV and congenital CMV.